Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease: an updated systematic review and meta-analysis of randomized controlled trials

  • Zhonghua Tian1
  • Yuxia Li2
  1. 1Department of Pharmacy, Chongqing Traditional Chinese Medicine Hospital
  2. 2Department of Nuclear Medicine, Chongqing Emergency Medical Center
Open at sourcePDFDOICite

Abstract

Aims: To evaluate the efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in diabetic kidney disease (DKD).

Methods: Following PRISMA 2020, we searched four databases to 31 July 2026, for randomized controlled trials (RCTs) comparing nsMRAs with placebo in adults with DKD. Pooled estimates used random-effects models, with mean differences (MDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed with Cochrane RoB 2, and certainty of evidence with GRADE.

Results: Eight RCTs (15,143 patients) were included. nsMRAs reduced log-transformed UACR (MD -0.36 log mg/g, 95% CI -0.44 to −0.28; n = 14,512 from 8 trials, predominantly driven by finerenone (5 of 8 trials), with significant drug-type interaction; P < 0.00001) and systolic BP (MD -4.72 mmHg, 95% CI -8.64 to −0.80; n = 7,538 from 3 trials (6 trials reported systolic BP; only 3 were poolable); predominantly driven by FIGARO-DKD; P = 0.02), but increased serum potassium (MD 0.22 mmol/L, 95% CI 0.16 to 0.29; n = 1,468 from 4 trials (6 trials reported serum potassium; FIDELIO-DKD and FIGARO-DKD excluded); P < 0.00001) and induced early eGFR decline (MD -3.01 mL/min/1.73 m ² , 95% CI -4.46 to −1.56; n = 1,218 from 3 trials; P < 0.0001). Hyperkalemia risk was higher (OR 2.24, 95% CI 1.99 to 2.52; n = 14,734 from 6 trials; P < 0.00001), whereas overall adverse events, eGFR decline, and acute kidney injury did not differ. GRADE certainty was low for UACR, systolic BP, serum potassium, and early eGFR decline, and moderate for hyperkalemia.

Conclusion: In DKD, nsMRAs may reduce UACR and systolic BP. However, UACR was driven by finerenone with significant drug-type interaction, requiring agent-specific interpretation. Systolic BP was driven by FIGARO-DKD. Furthermore, nsMRAs may increase serum potassium and hyperkalemia risk, although the serum potassium analysis excluded two large trials. nsMRAs may also cause early hemodynamic eGFR decline. Notably, this review assessed only surrogate endpoints and safety outcomes. Several outcomes were supported by only 3–4 trials. Given these limitations and low-to-moderate certainty, findings warrant cautious interpretation and risk-benefit assessment.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251072300 , identifier CRD420251072300.

Related

  1. Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
    Frances Perry, Silvia J. Leon, Kate Polecina +10
    Diabetes, Obesity & MetabolismPeer-reviewedCC BY-NC 4.0Full textEndocrinology & metabolismPMC
  2. Gonadotropin-releasing hormone antagonists versus agonists for endometriosis: a systematic review and meta-analysis of randomized controlled trials
    Tianmeng Liu, Yuhong Cai, Mingyang Li +5
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMCPMC
  3. Effects of mineralocorticoid receptor antagonists on coronary microcirculation: a mini-review.
    Yu Li, Zhenhong Zhang
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  4. Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD
    Berfu Korucu, Ayse Colak, Reem Mustafa +2
    Kidney International ReportsPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismDOAJEurope PMCPMC
  5. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{tian2026efficacy,
  title = {{Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease: an updated systematic review and meta-analysis of randomized controlled trials}},
  author = {Zhonghua Tian and Yuxia Li},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1983608},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1983608/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease: an updated systematic review and meta-analysis of randomized controlled trials
AU  - Zhonghua Tian
AU  - Yuxia Li
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1983608
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1983608/full
AB  - Aims: To evaluate the efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in diabetic kidney disease (DKD).  Methods: Following PRISMA 2020, we searched four databases to 31 July 2026, for randomized controlled trials (RCTs) comparing nsMRAs with placebo in adults with DKD. Pooled estimates used random-effects models, with mean differences (MDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed with Cochrane RoB 2, and certainty of evidence with GRADE.  Results: Eight RCTs (15,143 patients) were included. nsMRAs reduced log-transformed UACR (MD -0.36 log mg/g, 95% CI -0.44 to −0.28; n = 14,512 from 8 trials, predominantly driven by finerenone (5 of 8 trials), with significant drug-type interaction; P < 0.00001) and systolic BP (MD -4.72 mmHg, 95% CI -8.64 to −0.80; n = 7,538 from 3 trials (6 trials reported systolic BP; only 3 were poolable); predominantly driven by FIGARO-DKD; P = 0.02), but increased serum potassium (MD 0.22 mmol/L, 95% CI 0.16 to 0.29; n = 1,468 from 4 trials (6 trials reported serum potassium; FIDELIO-DKD and FIGARO-DKD excluded); P < 0.00001) and induced early eGFR decline (MD -3.01 mL/min/1.73 m ² , 95% CI -4.46 to −1.56; n = 1,218 from 3 trials; P < 0.0001). Hyperkalemia risk was higher (OR 2.24, 95% CI 1.99 to 2.52; n = 14,734 from 6 trials; P < 0.00001), whereas overall adverse events, eGFR decline, and acute kidney injury did not differ. GRADE certainty was low for UACR, systolic BP, serum potassium, and early eGFR decline, and moderate for hyperkalemia.  Conclusion: In DKD, nsMRAs may reduce UACR and systolic BP. However, UACR was driven by finerenone with significant drug-type interaction, requiring agent-specific interpretation. Systolic BP was driven by FIGARO-DKD. Furthermore, nsMRAs may increase serum potassium and hyperkalemia risk, although the serum potassium analysis excluded two large trials. nsMRAs may also cause early hemodynamic eGFR decline. Notably, this review assessed only surrogate endpoints and safety outcomes. Several outcomes were supported by only 3–4 trials. Given these limitations and low-to-moderate certainty, findings warrant cautious interpretation and risk-benefit assessment.  Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251072300 , identifier CRD420251072300.
SN  - 1663-9812
ER  -